U.S., Dec. 7 -- ClinicalTrials.gov registry received information related to the study (NCT03758950) titled 'Inhaled Mometasone to Promote Reduction in Vasoocclusive Events 2' on Nov. 28.

Brief Summary: The study team proposes a triple-blind, placebo-controlled, phase II clinical trial of once-daily inhaled mometasone for 48 weeks (with 4-week washout at study completion) in individuals with Sickle Cell Disease (SCD) who report episodic cough or wheeze (ECW) but do not have asthma. Patients will be recruited from and followed in SCD clinics at participating sites. The primary endpoint will be a reduction in sVCAM level of 20% or more in comparison to placebo.

Study Type: Interventional

Condition: Sickle Cell Disease

Intervention: * Drug:...